S-151128

S-151128 is an investigational small molecule inhibitor of the Nav1.7 sodium channel (Sodium channel protein type IX alpha subunit), developed through a collaboration between Shionogi and Hokkaido University. It is currently being evaluated for the treatment of chronic pain conditions, specifically knee osteoarthritis. By selectively targeting Nav1.7, a channel primarily expressed in peripheral sensory neurons and heavily implicated in pain signaling, S-151128 aims to provide analgesic effects with a reduced risk of central nervous system side effects. The drug is administered via intravenous injection and has progressed to Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics.